en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


 
2/2015
vol. 53
 
Share:
Share:
more
 
 
abstract:

Original paper
Changes in the morbidity and costs of systemic lupus erythematosus in Poland in the years 2008–2012

Andrzej Śliwczyński
,
Melania Brzozowska
,
Petre Iltchev
,
Tomasz Czeleko
,
Zbigniew Teter
,
Witold Tłustochowicz
,
Michał Marczak
,
Małgorzata Tłustochowicz

Reumatologia 2015; 53, 2: 79–86
Online publish date: 2015/05/18
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Objectives: The goal of the article is to present the changes in morbidity and costs of systemic lupus erythematosus (SLE) in Poland in the 2008–2012 period, depending on the province of residence of the patients based on data reported to the public payer – the National Health Fund.

Material and methods: Based on the ICD-10 code and the patient’s personal identity number, the number of patients and medical costs (cost of hospitalization, pharmaceutical, medical procedures, dialysis and specialist consultations) were calculated by province (voivodeship) and urban or rural residence.

Results: Annually on average in the assessed period in Poland approximately 20 000 patients were diagnosed with SLE. The studied group was dominated by women (they were 5.2 times more numerous). The morbidity rate was 52.183 patients per 100 thousand inhabitants. Most patients were in the age range of 48–56 years. Average annual expenses for this group of patients over the examined period were USD 16,327 million. Two times more was expended on patients inhabiting cities, approximately 4 times more on women. Calculated per patient, the average cost of therapy was USD 810.63.

Conclusions: The population of SLE patients in Poland is highly stable. The results of analysis indicate 1.64 times more frequent occurrence in urban areas, which may be connected with availability of doctors. The SLE treatment costs in Poland are much lower than in other countries, which is related mainly to the fact that therapy with biological drugs is not financed.
keywords:

epidemiology, systemic lupus erythematosus, regional differences, health economics







Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.